Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

Investors Business Daily

3 Dividend Growth Stocks to Buy and Hold

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again

Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.

Investors Business Daily

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

Lawsuits Against Gilead Sciences Could Stifle Medical Innovation

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.

inkl

Read news from The Economist, FT, and more,
with one subscription

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion

CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion

CymaBay stock skyrocketed Monday after Gilead Sciences announced it will buy it for $4.3 billion. CBAY stock surged almost 25%.

Investors Business Daily

Gilead Reports 'Mildly Disappointing' Quarterly Results With An Unexpected High Point

Gilead Reports 'Mildly Disappointing' Quarterly Results With An Unexpected High Point

Gilead had a "mildly disappointing" fourth quarter that featured two high-profile misses from HIV drugs. GILD stock hit a four-month low.

Investors Business Daily

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

How To Invest: The Slow Saucer Base Can Produce Quick Returns

How To Invest: The Slow Saucer Base Can Produce Quick Returns

Though it can technically be as short as seven weeks, most saucer bases develop over months or even years.

Investors Business Daily

Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction?

Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction?

Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled.

Investors Business Daily

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Gilead Tumbles After An Unpredictable Element Drove Its Third-Quarter Beat

Investors hammered GILD stock on Wednesday after Gilead beat third-quarter expectations on the back of its Covid treatment, Veklury.

Gilead Sciences (GILD) Earnings Forecast and Gameplan

Gilead Sciences (GILD) boasts an impressive product portfolio and has surpassed the consensus estimate on the topline in each of the trailing four quarters. With the company gearing up to post its third quarter results, is GILD a wise investment now? Read on.

Using Market Volatility to Your Advantage: Selling a GILD Put Option Before Earnings

A trader selling the November 10th, $76-strike put on GILD would receive around $105 into their account, which would be theirs to keep.

Investors Business Daily

Why AstraZeneca's Disappointing Lung Cancer Update Also Tripped Gilead Stock

AstraZeneca stock tumbled Wednesday after its experimental drug led to only a month's benefit over chemotherapy in lung cancer patients.

Get all your
news in one place.

100’s of premium titles.
One news app.

How to Enhance Your Own Strategies with POWR Ratings

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

Investors Business Daily

The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month

Investors don't fully appreciate Gilead Sciences' leadership in HIV treatment, an analyst said Friday as he upgraded GILD stock.

3 strong and undervalued dividend stocks: Morningstar

Dividend stocks often provide steady – sometimes rising – income payments and a potential for capital gains.

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

Big Pharma’s playbook for expensive meds

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Major brands are pulling ads on Musk's X after posts appeared beside pro-Nazi content

"If trust is lost it's like a house of cards—and currently X lacks trust from both its audiences and its B2B partners."

1 2 3 4 5

People

Dipanjan BanchurSince

Linda Yaccarino

Steven AdamsAfter

Susan Dziubinski

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Developing Countries

Places

243,685 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play